Online citations, reference lists, and bibliographies.
← Back to Search

Recommendations For The Use Of Botulinum Toxin Type A In The Management Of Cerebral Palsy.

H. Graham, K. Aoki, I. Autti-Rämö, R. Boyd, M. Delgado, D. Gaebler-Spira, M. E. Gormley, B. M. Guyer, F. Heinen, A. Holton, D. Matthews, G. Molenaers, F. Motta, P. G. García Ruiz, J. Wissel
Published 2000 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Botulinum toxin type A (BTX-A) is increasingly being used for the treatment of childhood spasticity, particularly cerebral palsy. However, until very recently, all such use in this indication has been unapproved with no generally accepted treatment protocols, resulting in considerable uncertainty and variation in its use as a therapeutic agent. In view of the increasing awareness of, and interest in, this approach to the treatment of spasticity, and also the recent licensing in a number of countries of a BTX-A preparation for treating equinus deformity in children, it would seem timely to establish a framework of guidelines for the safe and efficacious use of BTX-A for treating spasticity in children. This paper represents an attempt, by a group of 15 experienced clinicians and scientists from a variety of disciplines, to arrive at a consensus and produce detailed recommendations as to appropriate patient selection and assessment, dosage, injection technique and outcome measurement. The importance of adjunctive physiotherapy, orthoses and casting is also stressed.
This paper references
10.1111/j.1469-8749.1999.tb00589.x
The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response
N. Eames (1999)
Botulinum toxin A in the management of children with cerebral palsy: indications and outcome
R. Boyd (1997)
10.1007/PL00004951
Botulinum A toxins: units versus units
K. Wohlfarth (1997)
10.1016/0002-9394(86)90601-X
Absence of antibody production in patients treated with botulinum A toxin.
A. W. Biglan (1986)
10.1002/MDS.870090216
Development of resistance to botulinum toxin type A in patients with torticollis
P. Greene (1994)
10.1006/SMNS.1994.1020
Probing the process of transmitter release with botulinum and tetanus neurotoxins
J. O. Dolly (1994)
10.1111/j.1469-8749.2000.tb00022.x
Biomechanical transformation of the gastroc‐soleus muscle with botulinum toxin A in children with cerebral palsy
R. Boyd (2000)
10.1212/WNL.43.4.834
Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia
J. Jankovic (1993)
10.1212/WNL.45.1.204
Antibodies to botulinum toxin
G. Borodic (1995)
10.1177/014107689208500906
Botulinum toxin treatment of spasmodic torticollis.
T. J. Anderson (1992)
10.1016/S0966-6362(99)00012-0
Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy.
D. Sutherland (1999)
10.1097/01241398-199805000-00006
Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.
I. Corry (1998)
10.1016/0966-6362(95)01054-8
Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis study
D. Sutherland (1996)
Occupational Therapy for Physical Dysfunction
C. Trombly (1977)
10.1055/S-2007-979757
Dystonic posture of lower extremities associated with myelomeningocele: successful treatment with botulinum A toxin in a six-month-old child.
F. Heinen (1995)
10.1097/01241398-199905000-00015
Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection.
M. Massin (1999)
10.1016/S0966-6362(99)00037-5
Botulinum toxin A in hamstring spasticity.
I. Corry (1999)
10.1111/j.1468-1331.1999.tb00033.x
Medium‐term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy
R. Boyd (1999)
10.1016/S0140-6736(05)64586-2
Transient urinary incontinence after botulinum A toxin
R. Boyd (1996)
10.1016/0002-9394(88)90016-5
Negative antibody response to long-term treatment of facial spasm with botulinum toxin.
R. Gonnering (1988)
10.1006/exnr.1997.6580
Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences
H. Göschel (1997)
Botulinum Toxin Type A: From Toxin to Therapeutic Agent
Hong-Ting Chan (1999)
10.1002/MDS.870020402
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M. Brin (1987)
10.1212/WNL.43.9.1715
Botulinum antibodies in dystonic patients treated with type A botulinum toxin
M. Zuber (1993)
10.1016/S0140-6736(94)90153-8
Dose standardisation of botulinum toxin
EricR. First (1994)
10.1038/365160A0
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25
J. Blasi (1993)
10.1007/BF00499891
Local tetanus in cats: The influence of neuromuscular activity on spinal distribution of 125I labelled tetanus toxin
H. Wellhöner (2004)
10.1016/0301-0082(95)00003-E
Molecular aspects of tetanus and botulinum neurotoxin poisoning
G. Ahnert-Hilger (1995)
10.5014/AJOT.35.4.237
A developmental prehension assessment for handicapped children.
R. Erhardt (1981)
10.1055/S-2007-973475
Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment.
J. Wissel (1999)
10.1055/S-2007-973721
Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A.
F. Heinen (1997)
10.1073/PNAS.96.6.3200
Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.
A. de Paiva (1999)
10.1111/j.1469-8749.1997.tb07501.x
Botulinum toxin treatment in cerebral palsy: intervention with poor evaluation?
H. Forssberg (1997)
10.1097/01241398-199405000-00005
Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.
L. Koman (1994)
10.1177/000841748505200505
Box and Block Test of Manual Dexterity: Norms for 6–19 Year Olds
V. Mathiowetz (1985)
10.1002/MDS.870120627
DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
C. Sampaio (1997)
10.1111/j.1468-1331.1999.tb00032.x
Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations
K. Aoki (1999)
10.1111/j.1468-1331.1999.tb00031.x
Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy
R. Boyd (1999)
The pharmacokinetics of Norpace.
A. Karim (1975)
10.1016/0306-4522(90)90109-H
Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type a toxin: Morphological and electrophysiological features
D. Angaut-Petit (1990)
10.1111/j.1469-8749.1989.tb04003.x
THE GROSS MOTOR FUNCTION MEASURE: A MEANS TO EVALUATE THE EFFECTS OF PHYSICAL THERAPY
D. Russell (1989)
Botulinum toxin potency: a mystery resolved by the median paralysis.
L. Pearce (1994)
10.1111/j.1469-8749.1994.tb11864.x
BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY
A. Cosgrove (1994)
10.1093/PTJ/67.2.206
Interrater reliability of a modified Ashworth scale of muscle spasticity.
R. Bohannon (1987)
10.1007/BF00499890
Local tetanus in cats: Neuropharmacokinetics of 125I-tetanus toxin
H. Wellhöner (2004)
10.1002/MDS.870090106
Histologic assessment of dose‐related diffusion and muscle fiber response after therapeutic botulinum a toxin injections
G. Borodic (1994)



This paper is referenced by
10.1007/s00115-010-3172-8
Botulinum-Neurotoxin in der Behandlung der Spastizität im Erwachsenenalter
Julia Wissel (2010)
10.3109/15569543.2014.896020
Potential of Botulinum toxin A to treat upper extremity spasticity in children with cerebral palsy
Irene Nikaina (2014)
10.1097/01.PHM.0000104680.28335.B9
Intraparotid Injection of Botulinum Toxin A as a Treatment to Control Sialorrhea in Children with Cerebral Palsy
Robert Savarese (2004)
10.1002/mds.20088
Use of botulinum toxin in pediatric spasticity (cerebral palsy)
S. Berweck (2004)
10.1016/j.cellsig.2018.10.014
Chemical denervation using botulinum toxin increases Akt expression and reduces submaximal insulin-stimulated glucose transport in mouse muscle.
Z. Li (2019)
10.1007/978-3-642-12915-5_35
Neurorehabilitation im Kindesund Jugendalter
Wolfgang Deppe (2010)
10.1097/00003086-200201000-00021
Repeated Botulinum Toxin A Injections in the Treatment of Spastic Equinus Foot
D. Metaxiotis (2002)
10.1177/0883073807299975
Botulinum Toxin Type B Improves the Speed of Reaching in Children With Cerebral Palsy and Arm Dystonia: An Open-Label, Dose-Escalation Pilot Study
T. Sanger (2007)
10.1097/BPO.0b013e31825eb2a6
Management of Children With Ambulatory Cerebral Palsy: An Evidence-based Review
U. Narayanan (2012)
10.1016/j.jneuroim.2017.02.014
Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules
M. Oshima (2017)
10.1016/S0168-6054(07)80003-1
Utilisation de fortes doses de toxine botulique de type A chez l'enfant: intérêt et sécurité en pratique clinique
P. Filipetti (2007)
10.1038/pr.2016.153
Maternal creatine supplementation during pregnancy prevents acute and long-term deficits in skeletal muscle after birth asphyxia: a study of structure and function of hind limb muscle in the spiny mouse
Domenic A. LaRosa (2016)
10.1097/01202412-200609000-00007
Use of videographic examination for analysis of efficacy of botulinum toxin in the lower limbs in children with cerebral palsy
E. Chaléat-Valayer (2006)
10.1590/0004-282X20140020
Side-to-side growth discrepancies in children with hemiplegic cerebral palsy: association with function, activity and social participation.
M. Zonta (2014)
Funktionelle und anatomische Veränderungen des Bewegungsapparates durch selektive dorsale Rhizotomie bei Kindern mit bilateraler spastischer Cerebralparese
Julia Franziska Funk (2016)
Effects of Forward Tilting of Seat Surface on Arm-hand Mobility of Young Children with Bilateral Spastic Cerebral Palsy: a Preliminary Study
Mattana Angsupaisal (2017)
Children with spastic cerebral palsy : Aspects of muscle activity and botulinum toxin a treatment
K. Tedroff (2009)
10.1097/00002030-200401230-00036
Botulinum toxin in the treatment of spasticity in HIV-infected children affected with progressive encephalopathy.
A. Noguera (2004)
10.1097/BPO.0b013e3181b2f21d
The Effectiveness of Botulinum A Toxin as an Adjunct to the Treatment of Clubfeet by the Ponseti Method: A Randomized, Double Blind, Placebo Controlled Study
R. Cummings (2009)
10.1007/s00415-003-1044-x
Posterior CT guided approach for botulinum toxin injection into spinal psoas
P. G. García Ruiz (2003)
10.1016/S0168-6054(07)80001-8
Place des doses élevées dans les injections de toxine botulique
M. Rousseaux (2007)
10.1016/j.jbiomech.2010.08.020
Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox).
R. Fortuna (2011)
10.1016/J.GAITPOST.2004.12.002
Validation of a visual gait assessment scale for children with hemiplegic cerebral palsy.
Wendy E Dickens (2006)
10.1097/01202412-200511000-00001
Management of the Upper Limb in Cerebral Palsy
Terence Y. P. Chin (2005)
10.1177/08830738050200080501
Factors Predicting the Efficacy of Botulinum Toxin-A Treatment of the Lower Limb in Children With Cerebral Palsy
E. Fazzi (2005)
10.1016/S0035-1040(06)75782-8
L’infirmité motrice d’origine cérébrale (IMOC)
P. Lebarbier (2006)
EFFECT OF BOTULINUM TOXIN APPLICATION INTO PLANTAR FLEXOR MUSCLES ON GAIT PATTERN OF CHILDREN WITH CEREBRAL PALSY
VPLIV APLIKACIJE BOTULINSKEGA ()
10.11606/ISSN.2317-0190.V17I2A103312
Functionality evaluation of children with spastic cerebral palsy
M. M. Spósito (2009)
10.3233/NRE-141052
High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy.
D. Intiso (2014)
10.1016/J.PEDIATRNEUROL.2007.05.019
Calf muscle volume estimates: implications for botulinum toxin treatment?
T. Bandholm (2007)
10.1016/J.PAED.2007.09.009
Managing spasticity in children
Mhorag E.A. Duff (2007)
10.1007/s10198-004-0224-7
Costs and consequences of botulinum toxin type A use
F. J. Ruiz (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar